Currently trading at a $274 million market valuation
ELTP does have $11 million in the treasury, manageable debt and fast
growing revenues reporting $7,079,772 in sales for the 3 months ended
June, 30, 2015. The stock has fast quickly become an Investors favorite;
ELTP is fully-funded moving forward, the Company has nineteen FDA
approved drugs to be manufactured, approximately eighteen more in the
pipeline in various stages with numerous partners, and just announced
positive top-line results from the Phase 3 pivotal trial of its lead
opioid abuse-deterrent candidate, ELI-200, for the treatment of moderate
to severe pain.
MORE HERE
MORE HERE
No comments:
Post a Comment